Elicio Therapeutics Reports Inducement Grants

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) has granted 9,800 inducement stock options to two new employees on September 15, 2025. The options were priced at $10.08 per share with a four-year vesting schedule, starting with 25% vesting after the first year.

The company, specializing in novel immunotherapies for cancer treatment, highlighted its lead program ELI-002, an off-the-shelf vaccine targeting KRAS mutations. Recent Phase 1 AMPLIFY-201 data showed promising results with 16.3-month median recurrence-free survival and 28.9-month median overall survival in pancreatic and colorectal cancer patients.

Positive

• Strong clinical data with 16.3-month median recurrence-free survival and 28.9-month median overall survival in Phase 1 trial
• Development of off-the-shelf vaccines offering potential benefits of low cost and rapid manufacturing
• Pipeline expansion plans including treatments for lung cancer and other KRAS-positive cancers

Negative

• Stock options grants may lead to future dilution for existing shareholders

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

Each grant provides for the purchase of shares of Elicio common stock at a price of $10.08 per share, the closing price per share of Elicio common stock as reported by Nasdaq on September 15, 2025, the date of grant.

The grants vest over four years, with 25 percent of the shares vesting on the first anniversary of each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional vaccination strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 lead program is an off-the-shelf vaccine candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf vaccine approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized vaccines approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive pancreatic cancer who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. In the future, Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer vaccines candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

What are the terms of Elicio Therapeutics (ELTX) inducement stock options granted in September 2025?

Elicio granted 9,800 inducement stock options to two employees at $10.08 per share, vesting over 4 years with 25% vesting in the first year and the remainder monthly thereafter.

What are the latest clinical results for Elicio's ELI-002 cancer vaccine?

The AMPLIFY-201 Phase 1 data showed 16.3-month median recurrence-free survival and 28.9-month median overall survival for pancreatic and colorectal cancer patients.

What types of cancer does Elicio Therapeutics' ELI-002 target?

ELI-002 targets the most common KRAS mutations, which drive approximately 25% of all solid tumors, particularly focusing on pancreatic and colorectal cancers.

What are the advantages of Elicio's off-the-shelf vaccine approach?

The off-the-shelf approach offers benefits including lower costs, rapid commercial scale manufacturing, and quick availability to patients, especially in neo-adjuvant settings and for high-risk patient prophylaxis.

What other pipeline candidates is Elicio developing besides ELI-002?

Elicio is developing ELI-007 for BRAF-driven cancers and ELI-008 for p53 hotspot mutations as additional off-the-shelf therapeutic cancer vaccines.